Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to -$550000.0.

  • Rani Therapeutics Holdings' Change in Accured Expenses rose 1228.07% to -$550000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $297000.0, marking a year-over-year increase of 11409.59%. This contributed to the annual value of $350000.0 for FY2024, which is 16481.48% up from last year.
  • Per Rani Therapeutics Holdings' latest filing, its Change in Accured Expenses stood at -$550000.0 for Q3 2025, which was up 1228.07% from $388000.0 recorded in Q2 2025.
  • In the past 5 years, Rani Therapeutics Holdings' Change in Accured Expenses ranged from a high of $1.4 million in Q2 2023 and a low of -$2.2 million during Q4 2023
  • For the 5-year period, Rani Therapeutics Holdings' Change in Accured Expenses averaged around $61157.9, with its median value being $323000.0 (2023).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 145294.12% in 2021, then plummeted by 69367.09% in 2024.
  • Over the past 5 years, Rani Therapeutics Holdings' Change in Accured Expenses (Quarter) stood at -$1.6 million in 2021, then fell by 11.08% to -$1.8 million in 2022, then decreased by 21.46% to -$2.2 million in 2023, then surged by 113.33% to $289000.0 in 2024, then tumbled by 290.31% to -$550000.0 in 2025.
  • Its last three reported values are -$550000.0 in Q3 2025, $388000.0 for Q2 2025, and $170000.0 during Q1 2025.